Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation SequencingInvivoscribe Marketing2024-03-26T13:55:01-07:00March 20th, 2024|2024 Publications, Featured Publications, Publications| Read more
Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myelomaInvivoscribe Marketing2024-03-26T13:50:51-07:00March 19th, 2024|2024 Publications, Featured Publications, Publications| Read more
Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell NeoplasmsInvivoscribe Marketing2024-03-03T11:41:21-08:00March 1st, 2024|2024 Publications, Featured Publications, Publications| Read more
JSLM Annual Meeting 2024Invivoscribe Marketing2024-02-16T16:13:53-08:00November 28th, 2023|Conferences| Read more
The Evolving Role of NGS and Measurable Residual Disease in CLL/SLL and AMLInvivoscribe Marketing2024-02-08T15:09:04-08:00November 16th, 2023|2023 Videos, Featured Videos, Videos| Watch video
EA4HP-SH 2024Invivoscribe Marketing2024-02-16T16:12:53-08:00September 21st, 2023|Conferences| Read more
CMACSH Chinese Society of Hematology Conference 2024Invivoscribe Marketing2024-02-16T16:06:24-08:00September 20th, 2023|Conferences| Read more
CGC Annual Meeting 2024Invivoscribe Marketing2024-02-16T16:04:32-08:00August 4th, 2023|Conferences| Read more
Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTAInvivoscribe Marketing2023-07-20T17:27:41-07:00July 21st, 2023|2023 Press Releases, Press Releases| Read more
MRD Applications and AnalysisInvivoscribe Marketing2023-07-11T18:20:48-07:00June 20th, 2023|2023 Videos, Featured Videos, Videos| Watch video
Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer ResearchInvivoscribe Marketing2023-06-05T12:37:16-07:00June 2nd, 2023|2023 Press Releases, Press Releases| Read more
NGS Assessment of SHM in CLL/SLL: A Practical Comparison of Platforms and PrimersInvivoscribe Marketing2023-06-06T16:30:52-07:00May 31st, 2023|2023 Videos, Featured Videos, Videos| Watch video
Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in JapanInvivoscribe Marketing2023-05-25T17:09:22-07:00May 25th, 2023|2023 Press Releases, Press Releases| Read more
CMA Leukemia and Lymphoma Conference 2024Invivoscribe Marketing2024-02-16T16:02:59-08:00May 17th, 2023|Conferences| Read more
JAMT Congress 2024Invivoscribe Marketing2024-02-16T16:01:16-08:00May 11th, 2023|Conferences| Read more
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation AssayInvivoscribe Marketing2023-05-11T03:12:47-07:00May 11th, 2023|2023 Press Releases, Press Releases| Read more
Multiparameter Approach to CLL Diagnosis, Prognostic Biomarker Assessment, and MRD MonitoringInvivoscribe Marketing2023-03-09T08:51:36-08:00February 28th, 2023|2023 Videos, Featured Videos, Videos| Watch video
Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in ChinaInvivoscribe Marketing2023-02-23T06:28:40-08:00February 23rd, 2023|2023 Press Releases, Press Releases| Read more